Advertisement

The Latest

Tempus and New York City-based NYU Langone Health have formed a multi-year strategic collaboration to advance cancer research through molecular profiling and data-driven insights. The partnership will support NYU Langone Health’s Center for Molecular Oncology at the Laura and Isaac…

Mark Smith has been appointed president and CEO of AdventHealth Littleton in Colorado. Mr. Smith most recently served as president and CEO of AdventHealth Avista in Louisville, Colo., according to a Jan. 9 LinkedIn post from AdventHealth Colorado. He began…

UnitedHealth Group leveraged “aggressive strategies” to get higher-paying Medicare Advantage diagnoses, according to a Jan. 12 Senate report that Becker’s viewed. The Wall Street Journal initially covered the news. Senate Judiciary Chair Chuck Grassley, R-Iowa, launched an investigation into the…

In recent years, a swell of states has adopted laws to lessen the requirements for foreign-trained physicians to join the U.S. workforce.   The laws aim to combat the nation’s growing physician shortage, which is becoming more urgent as patient acuity…

Tampa (Fla.) General Hospital and Somerville, Mass.-based Mass General Brigham have launched a joint ambulatory care network to serve Florida’s East Coast and expand outpatient services. The joint venture will provide advanced imaging, oncology, outpatient surgery, primary care and specialty…

Sabrina Kidd, MD, has been appointed chief medical officer of Centerpoint Medical Center in Independence, Mo., part of Nashville, Tenn.-based HCA Healthcare. Dr. Kidd is a certified physician executive and dual board-certified colorectal and general surgeon, according to a Dec.…

Dignity Health-Glendale (Calif.) Memorial Hospital and Health Center is marking its centennial, reflecting what its president and CEO described as a long-standing commitment to healing and human kindness. “We’re incredibly excited about the centennial,” Betsy Hart, MSN, RN, said. “For…

Atara Biotherapeutics received a second complete response letter from the FDA for its biologics license application for Ebvallo (tabelecleucel). The letter, received Jan. 9, said the FDA no longer considers the single-arm ALLELE trial adequate to support accelerated approval for…

Advertisement